Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer's Disease Treatment

被引:29
作者
Poor, Saghar Rabiei [1 ,2 ,3 ]
Ettcheto, Miren [3 ,4 ]
Cano, Amanda [4 ,5 ,6 ,7 ]
Sanchez-Lopez, Elena [4 ,6 ,7 ]
Manzine, Patricia Regina [3 ,8 ]
Olloquequi, Jordi [9 ]
Camins, Antoni [3 ,4 ,5 ,9 ]
Javan, Mohammad [1 ,2 ,10 ]
机构
[1] Tarbiat Modares Univ, Dept Physiol, Fac Med Sci, Tehran 1411713116, Iran
[2] Tarbiat Modares Univ, Inst Brain & Cognit, Tehran 1411713116, Iran
[3] Univ Barcelona, Dept Pharmacol Toxicol & Therapeut Chem, Fac Pharm & Food Sci, Inst Neurociencies, Barcelona 08028, Spain
[4] Biomed Res Networking Ctr Neurodegenerat Dis CIBE, Madrid 08028, Spain
[5] Univ Int Catalunya UIC, Ace Alzheimer Ctr Barcelona, Barcelona 08028, Spain
[6] Inst Nanosci & Nanotechnol IN2UB, Barcelona 08028, Spain
[7] Univ Barcelona, Fac Pharm & Food Sci, Dept Pharm Pharmaceut Technol & Phys Chem, Barcelona 08028, Spain
[8] Fed Univ Sao Carlos UFSCar, Dept Gerontol, BR-13565905 Sao Carlos, Brazil
[9] Univ Autonoma Chile, Lab Cellular & Mol Pathol, Inst Biomed Sci, Fac Hlth Sci, Talca 3467987, Chile
[10] ACECR, Dept Brain & Cognit Sci, Cell Sci Res Ctr, Royan Inst Stem Cell Biol & Technol, Tehran 1411713116, Iran
基金
美国国家科学基金会; 巴西圣保罗研究基金会;
关键词
Alzheimer's disease; diabetes mellitus; metformin; insulin resistance; beta amyloid; tau protein hyperphosphorylation; AMP activated protein kinase (AMPK); HEPATIC INSULIN-RESISTANCE; DIABETES-MELLITUS; HIPPOCAMPAL NEUROGENESIS; INCIDENT DEMENTIA; COGNITIVE DECLINE; MEMORY IMPAIRMENT; SYNAPTIC LOSS; MOUSE MODEL; BRAIN; RISK;
D O I
10.3390/ph14090890
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alzheimer's disease (AD) is one of the most devastating brain disorders. Currently, there are no effective treatments to stop the disease progression and it is becoming a major public health concern. Several risk factors are involved in the progression of AD, modifying neuronal circuits and brain cognition, and eventually leading to neuronal death. Among them, obesity and type 2 diabetes mellitus (T2DM) have attracted increasing attention, since brain insulin resistance can contribute to neurodegeneration. Consequently, AD has been referred to "type 3 diabetes" and antidiabetic medications such as intranasal insulin, glitazones, metformin or liraglutide are being tested as possible alternatives. Metformin, a first line antihyperglycemic medication, is a 5 '-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator hypothesized to act as a geroprotective agent. However, studies on its association with age-related cognitive decline have shown controversial results with positive and negative findings. In spite of this, metformin shows positive benefits such as anti-inflammatory effects, accelerated neurogenesis, strengthened memory, and prolonged life expectancy. Moreover, it has been recently demonstrated that metformin enhances synaptophysin, sirtuin-1, AMPK, and brain-derived neuronal factor (BDNF) immunoreactivity, which are essential markers of plasticity. The present review discusses the numerous studies which have explored (1) the neuropathological hallmarks of AD, (2) association of type 2 diabetes with AD, and (3) the potential therapeutic effects of metformin on AD and preclinical models.
引用
收藏
页数:22
相关论文
共 156 条
  • [1] The protective effect of metformin in scopolamine-induced learning and memory impairment in rats
    Aksoz, Elif
    Gocmez, Semil Selcen
    Sahin, Tugce Demirtas
    Aksit, Dilek
    Aksit, Hasan
    Utkan, Tijen
    [J]. PHARMACOLOGICAL REPORTS, 2019, 71 (05) : 818 - 825
  • [2] 2021 Alzheimer's disease facts and figures
    不详
    [J]. ALZHEIMERS & DEMENTIA, 2021, 17 (03) : 327 - 406
  • [3] Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function
    Arvanitakis, Zoe
    Wang, Hoau-Yan
    Capuano, Ana W.
    Khan, Amber
    Taib, Bouchra
    Anokye-Danso, Frederick
    Schneider, Julie A.
    Bennett, David A.
    Ahima, Rexford S.
    Arnold, Steven E.
    [J]. ANNALS OF NEUROLOGY, 2020, 88 (03) : 513 - 525
  • [4] Neuroprotective effects of metformin against Aβ-mediated inhibition of long-term potentiation in rats fed a high-fat diet
    Asadbegi, Masoumeh
    Yaghmaei, Parichehreh
    Salehi, Iraj
    Ebrahim-Habibi, Azadeh
    Komaki, Alireza
    [J]. BRAIN RESEARCH BULLETIN, 2016, 121 : 178 - 185
  • [5] A Multilevel View of the Development of Alzheimer's Disease
    Avila, Jesus
    Perry, George
    [J]. NEUROSCIENCE, 2021, 457 : 283 - 293
  • [6] Drug repositioning and repurposing for Alzheimer disease
    Ballard, Clive
    Aarsland, Dag
    Cummings, Jeffrey
    O'Brien, John
    Mills, Roger
    Molinuevo, Jose Luis
    Fladby, Tormod
    Williams, Gareth
    Doherty, Pat
    Corbett, Anne
    Sultana, Janet
    [J]. NATURE REVIEWS NEUROLOGY, 2020, 16 (12) : 661 - 673
  • [7] Sex Differences in the Cognitive and Hippocampal Effects of Streptozotocin in an Animal Model of Sporadic AD
    Bao, Jian
    Mahaman, Yacoubou A. R.
    Liu, Rong
    Wang, Jian-Zhi
    Zhang, Zhiguo
    Zhang, Bin
    Wang, Xiaochuan
    [J]. FRONTIERS IN AGING NEUROSCIENCE, 2017, 9
  • [8] Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction
    Barber, Thomas M.
    Kyrou, Ioannis
    Randeva, Harpal S.
    Weickert, Martin O.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (02) : 1 - 16
  • [9] The projected effect of risk factor reduction on Alzheimer's disease prevalence
    Barnes, Deborah E.
    Yaffe, Kristine
    [J]. LANCET NEUROLOGY, 2011, 10 (09) : 819 - 828
  • [10] Bendlin BB, 2019, DIALOGUES CLIN NEURO, V21, P83